Through a screening assay of cell line toxicity on a panel of lung cancer cells, we found that trametinib and bosutinib, inhibitors of MEK and SRC kinases, respectively, showed potential synergistic inhibition effects on cell proliferation in both NSCLC and erlotinib-resistant NSCLC. Here, SRC is linked to non-small cell lung carcinoma.